Drug intelligence / Profile preview

JNJ-87189401 + JNJ-78278343

Development stage: Unknown
Lead developer: Janssen Research & Development
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JNJ-87189401 + JNJ-78278343 is a combination drug regimen being investigated for the treatment of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). - **JNJ-78278343 (pasritamig)** is a first-in-class, investigational T-cell-engaging bispecific antibody that binds to human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T cells[3][4][6]. This dual binding redirects T cells to recognize and kill KLK2-expressing prostate tumor cells, harnessing the immune system for targeted anti-tumor activity[3][6]. Pasritamig is being evaluated in patients who have progressed after multiple prior therapies[3]. - **JNJ-87189401** is a proprietary compound from Janssen/Johnson & Johnson, but publicly available information does not describe its structure, pharmacology, or independent indication. - The combination is currently under investigation, with ongoing clinical trials seeking the optimal regimen and evaluating safety, pharmacokinetics, and anti-tumor activity in prostate cancer[5].

Other names: pasritamig

Targets

HK2 (Hexokinase Type II)CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on JNJ-87189401 + JNJ-78278343.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-87189401 + JNJ-78278343.

Explore the full profile